NYMC Faculty Publications

International Pediatric Non-Hodgkin Lymphoma Response Criteria

John T. Sandlund, John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; Angelo Rosolen, University of Padova, Padova, Italy; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig-University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY.
R Paul Guillerman, John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; Angelo Rosolen, University of Padova, Padova, Italy; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig-University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY.
Sherrie L. Perkins, John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; Angelo Rosolen, University of Padova, Padova, Italy; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig-University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY.
C Ross Pinkerton, John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; Angelo Rosolen, University of Padova, Padova, Italy; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig-University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY.
Angelo Rosolen, John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; Angelo Rosolen, University of Padova, Padova, Italy; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig-University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY.
Catherine Patte, John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; Angelo Rosolen, University of Padova, Padova, Italy; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig-University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY.
Alfred Reiter, John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; Angelo Rosolen, University of Padova, Padova, Italy; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig-University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY.
Mitchell S. Cairo, John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; Angelo Rosolen, University of Padova, Padova, Italy; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig-University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY. mitchell_cairo@nymc.edu.

Author Type(s)

Faculty

DOI

10.1200/JCO.2014.59.0745

Journal Title

Journal of Clinical Oncology

First Page

2106

Last Page

11

Document Type

Article

Publication Date

6-20-2015

Abstract

PURPOSE: Response criteria are well established for adult patients with non-Hodgkin lymphoma (NHL). A revised set of response criteria in adults with NHL was recently published. However, NHL in children and adolescents involves different histologies, primary sites of disease, patterns of metastatic spread, approaches to therapy, and responses to treatment compared with adult NHL. However, there are no standardized response criteria specific to pediatric NHL. Therefore, we developed international standardized methods for assessing response to therapy in children and adolescents with NHL. METHODS: An international multidisciplinary group of pediatric oncologists, pathologists, biologists, and radiologists convened during and after the Third and Fourth International Childhood, Adolescent and Young Adult NHL Symposia to review existing response and outcome data, develop methods for response evaluation that reflect incorporation of more sensitive technologies currently in use, and incorporate primary and metastatic sites of disease for the evaluation of therapeutic response in children and adolescents with NHL. RESULTS: Using the current adult NHL response criteria as a starting point, international pediatric NHL response criteria were developed incorporating both contemporary diagnostic imaging and pathology techniques, including novel molecular and flow cytometric technologies used for the determination of minimal residual disease. CONCLUSION: Use of the international pediatric NHL response criteria in children and adolescents receiving therapy for NHL incorporates data obtained from new and more sensitive technologies that are now being widely used for disease evaluation, providing a standardized means for reporting treatment response.

This document is currently not available here.

Share

COinS